---
figid: PMC9630162__gr3
pmcid: PMC9630162
image_filename: gr3.jpg
figure_link: /pmc/articles/PMC9630162/figure/fig3/
number: Figure 3
figure_title: ''
caption: Participants with PI3K/AKT/PTEN pathway-altered tumours identified by the
  expanded biomarker testing and compared with the original testing resultsMultiple
  colours indicate that a participant tumour carried two or more types of pathway
  alteration.
article_title: 'Fulvestrant plus capivasertib versus placebo after relapse or progression
  on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative
  breast cancer (FAKTION): overall survival, updated progression-free survival, and
  expanded biomarker analysis from a randomised, phase 2 trial.'
citation: Sacha J Howell, et al. Lancet Oncol. 2022 Jul;23(7):851-864.
year: '2022'

doi: 10.1016/S1470-2045(22)00284-4
journal_title: The Lancet. Oncology
journal_nlm_ta: Lancet Oncol
publisher_name: Lancet Pub. Group

keywords:
---
